- Home
- SLNO vs VRDN Comparison
SLNO vs VRDN Comparison
Compare SLNO & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLNO | VRDN |
|---|---|---|
| Founded | 1999 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.7B |
| IPO Year | 2014 | 2014 |
Fundamental Metrics
Financial Performance| Metric | SLNO | VRDN |
|---|---|---|
| Price | $52.63 | $15.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 14 |
| Target Price | ★ $90.13 | $36.00 |
| AVG Volume (30 Days) | ★ 5.5M | 3.2M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 108.90 | N/A |
| EPS | ★ 0.39 | N/A |
| Revenue | $1,450,788.00 | ★ $5,706,000.00 |
| Revenue This Year | $151.77 | $28.34 |
| Revenue Next Year | $53.58 | $235.57 |
| P/E Ratio | $134.99 | ★ N/A |
| Revenue Growth | ★ 138.82 | N/A |
| 52 Week Low | $29.43 | $11.76 |
| 52 Week High | $89.12 | $34.29 |
Technical Indicators
Market Signals| Indicator | SLNO | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 77.58 | 25.76 |
| Support Level | $48.91 | $13.59 |
| Resistance Level | $55.47 | $19.03 |
| Average True Range (ATR) | 1.49 | 1.32 |
| MACD | 2.06 | -0.56 |
| Stochastic Oscillator | 99.72 | 11.86 |
Price Performance
Historical ComparisonAbout SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).